NASDAQ:TOI Oncology Institute (TOI) Stock Price, News & Analysis $2.48 -0.02 (-0.80%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Oncology Institute Stock (NASDAQ:TOI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oncology Institute alerts:Sign Up Key Stats Today's Range$2.17▼$2.5250-Day Range$0.61▼$3.3152-Week Range$0.13▼$3.50Volume2.25 million shsAverage Volume822,437 shsMarket Capitalization$187.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewThe Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.Read More… Oncology Institute Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreTOI MarketRank™: Oncology Institute scored higher than 11% of companies evaluated by MarketBeat, and ranked 905th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Oncology Institute. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncology Institute is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncology Institute is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncology Institute has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Oncology Institute's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.15% of the float of Oncology Institute has been sold short.Short Interest Ratio / Days to CoverOncology Institute has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncology Institute has recently increased by 4.65%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOncology Institute does not currently pay a dividend.Dividend GrowthOncology Institute does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.15% of the float of Oncology Institute has been sold short.Short Interest Ratio / Days to CoverOncology Institute has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncology Institute has recently increased by 4.65%, indicating that investor sentiment is decreasing. News and Social Media2.1 / 5News Sentiment0.85 News SentimentOncology Institute has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Oncology Institute this week, compared to 2 articles on an average week.Search Interest7 people have searched for TOI on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Oncology Institute insiders have bought more of their company's stock than they have sold. Specifically, they have bought $127,148.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.50% of the stock of Oncology Institute is held by insiders.Percentage Held by InstitutionsOnly 36.86% of the stock of Oncology Institute is held by institutions.Read more about Oncology Institute's insider trading history. Receive TOI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncology Institute and its competitors with MarketBeat's FREE daily newsletter. Email Address TOI Stock News HeadlinesThe Oncology Institute Announces First Quarter 2025 Earnings Release Date and Conference CallApril 23, 2025 | globenewswire.comTopicus.com Inc. Announces Release Date for First Quarter ResultsApril 14, 2025 | globenewswire.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…April 30, 2025 | Paradigm Press (Ad)The Oncology Institute, Inc. (TOI): Among Stocks Insiders Were Buying In Q1 2025April 1, 2025 | msn.comThe Oncology Institute announces launch of the Florida Oncology NetworkMarch 31, 2025 | markets.businessinsider.comTOI Launches Florida Oncology Network, a Fully Delegated Cancer Care Network, and Announces Four Additional Value-based Contracts in Q1March 31, 2025 | globenewswire.comQ4 2024 Oncology Institute Inc Earnings CallMarch 26, 2025 | finance.yahoo.comOncology Institute Full Year 2024 Earnings: US$0.86 loss per share (vs US$0.92 loss in FY 2023)March 26, 2025 | uk.finance.yahoo.comSee More Headlines TOI Stock Analysis - Frequently Asked Questions How have TOI shares performed this year? Oncology Institute's stock was trading at $0.3090 at the start of the year. Since then, TOI shares have increased by 702.6% and is now trading at $2.48. View the best growth stocks for 2025 here. How were Oncology Institute's earnings last quarter? The Oncology Institute, Inc. (NASDAQ:TOI) issued its quarterly earnings data on Monday, March, 24th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.06. The company earned $100.27 million during the quarter, compared to analyst estimates of $109.15 million. Oncology Institute had a negative net margin of 17.63% and a negative trailing twelve-month return on equity of 186.83%. Read the conference call transcript. How do I buy shares of Oncology Institute? Shares of TOI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oncology Institute own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncology Institute investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), AppLovin (APP) and CrowdStrike (CRWD). Company Calendar Last Earnings3/24/2025Today4/30/2025Next Earnings (Estimated)5/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Offices & clinics of medical doctors Sub-IndustryHealthcare Current SymbolNASDAQ:TOI CIK1799191 Webtheoncologyinstitute.com Phone562-735-3226FaxN/AEmployees660Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,070,000.00 Net Margins-17.63% Pretax Margin-18.62% Return on Equity-186.83% Return on Assets-34.58% Debt Debt-to-Equity Ratio5.91 Current Ratio2.49 Quick Ratio2.27 Sales & Book Value Annual Sales$393.41 million Price / Sales0.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book3.22Miscellaneous Outstanding Shares75,559,000Free Float68,381,000Market Cap$187.39 million OptionableNot Optionable Beta0.22 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:TOI) was last updated on 4/30/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Oncology Institute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncology Institute With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.